(Alliance News) - OptiBiotix Health PLC on Monday noted the change in leadership at its recently AQSE-listed spin-off company ProBiotix Health PLC.
The York-based life sciences company hailed the appointment of Steen Anderson as chief executive officer of ProBiotix, in which it still holds a 44% stake.
Anderson has over 30 years of experience in the probiotics industry, having held posts as president of Deerland Probiotics & Enzymes, president & CEO of Bifodan, as well as president & CEO of Fluxome.
"The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution. Having established international sales and brand awareness of its award winning LPLDL probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LPLDL into other areas of health, and increasing access to the USA and Asian markets," commented OptiBiotix CEO
Stephen O'Hara.
Shares in OptiBiotix were untraded in London on Monday morning, last quoted at 21.35 pence.
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
OptiBiotix Health (OPTI)